Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 32Recruiting 4Terminated 3Not yet recruiting 3Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Rosuvastatin Calcium × Clear all
NCT05828303 2025-04-01

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT02483871 2017-06-05

Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy

Duke University

Phase 1 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡